このページの翻訳は実験的なもので、現在開発中です。お待ちしております

OssDsign マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Morten Henneveld

最高経営責任者

SEK 7.9m

報酬総額

CEO給与比率	54.0%
CEO在任期間	4yrs
CEOの所有権	0.2%
経営陣の平均在職期間	3.8yrs
取締役会の平均在任期間	5.7yrs

経営陣の近況

Recent updates

CEO報酬分析

OssDsign の収益と比較して、Morten Henneveld の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-SEK 114m
Mar 31 2024	n/a	n/a	-SEK 118m
Dec 31 2023	SEK 8m	SEK 4m	-SEK 130m
Sep 30 2023	n/a	n/a	-SEK 109m
Jun 30 2023	n/a	n/a	-SEK 95m
Mar 31 2023	n/a	n/a	-SEK 99m
Dec 31 2022	SEK 6m	SEK 4m	-SEK 99m
Sep 30 2022	n/a	n/a	-SEK 96m
Jun 30 2022	n/a	n/a	-SEK 93m
Mar 31 2022	n/a	n/a	-SEK 95m
Dec 31 2021	SEK 6m	SEK 6m	-SEK 94m
Sep 30 2021	n/a	n/a	-SEK 90m
Jun 30 2021	n/a	n/a	-SEK 92m
Mar 31 2021	n/a	n/a	-SEK 90m
Dec 31 2020	SEK 1m	SEK 1m	-SEK 85m

報酬と市場: Mortenの総報酬 ($USD 762.10K ) は、 German市場 ($USD 434.45K ) の同規模の企業の平均を上回っています。

報酬と収益: Mortenの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Morten Henneveld (48 yo)

4yrs

在職期間

SEK 7,939,000

報酬

Mr. Morten Henneveld has been Chief Executive Officer at OssDsign AB (publ) since September 1, 2020. Mr. Henneveld serves as a Director at Sime Diagnostics Ltd., since October 2022. He is Senior Vice Presi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Morten Henneveld	Chief Executive Officer	4yrs	SEK 7.94m	0.20% SEK 122.9k
Anders Svensson	Chief Financial Officer	3.8yrs	データなし	0.085% SEK 50.9k
Tom Buckland	Chief Technical Officer	less than a year	データなし	データなし
Melanie Marshall	Vice President of Clinical & Medical Affairs	2.7yrs	データなし	データなし
Eric Patermo	Vice President of Sales US	4.7yrs	データなし	データなし

3.8yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: 5J6の経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Viktor Drvota	Independent Director	9.7yrs	データなし	データなし
Newton Aguiar	Independent Director	5.7yrs	SEK 250.00	0.10% SEK 61.3k
Simon Cartmell	Independent Chairman of the Board	8.4yrs	SEK 350.00	0.13% SEK 76.8k
Jill Schiaparelli	Independent Director	2.3yrs	SEK 250.00	データなし
Christer Fahraeus	Director	less than a year	データなし	データなし

5.7yrs

平均在職期間

59.5yo

平均年齢

経験豊富なボード: 5J6の取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

OssDsign マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

OssDsign AB (publ), Annual General Meeting, May 21, 2024

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.30 loss in 2Q 2023)

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings released: kr0.10 loss per share (vs kr0.30 loss in 1Q 2023)

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

Forecast breakeven date moved forward to 2024

Full year 2023 earnings released: kr1.60 loss per share (vs kr1.70 loss in FY 2022)

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Now 22% undervalued

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Forecast breakeven date moved forward to 2024

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

No longer forecast to breakeven

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.30 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.40 loss per share (vs kr0.40 loss in 2Q 2021)

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

First quarter 2022 earnings released: kr0.40 loss per share (vs kr1.10 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.

New Scientific Paper Further Confirms Osteointegration of OssDsign Cranial PSI Implants

First quarter 2021 earnings released: kr1.10 loss per share (vs kr1.00 loss in 1Q 2020)

Anders Svensson Joins OssDsign AB (Publ) as Chief Financial Officer

OssDsign AB (publ), Annual General Meeting, Jun 04, 2021

New 90-day low: €1.35

Full year 2020 earnings released: kr4.40 loss per share (vs kr5.46 loss in FY 2019)

Revenue misses expectations

OssDsign AB (publ) Announces New Clinical Data from 1,055 Cranioplasty Procedures

New 90-day low: €1.36

Chairman of the Board recently bought €26k worth of stock

Svensson's CFO Claes Lindblad Is Leaving the Company

Third quarter 2020 earnings released: kr1.10 loss per share

Revenue misses expectations

OssDsign AB (publ) to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.42

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.169392 million.

Earnings released

OssDsign AB (publ) Announces Chief Executive Officer Changes

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

マネジメント基準チェック /24